Intellia Therapeutics (Intellia Therapeutics) Net Income : $-485.50 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Intellia Therapeutics's Net Income for the three months ended in Mar. 2024 was $-107.44 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-485.50 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Intellia Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.12.

Intellia Therapeutics Net Income Historical Data

The historical data trend for Intellia Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Net Income Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income

Get a 7-Day Free Trial

-99.53

-134.23

-267.89

-474.19

-481.19

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income	Get a 7-Day Free Trial															-103.13	-123.68	-122.22	-132.16	-107.44

Intellia Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Intellia Therapeutics's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-481.192	+	0	+	0	+	0
=	-481.19

Intellia Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as

	Net Income		(Q: Mar. 2024 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-107.436	+	0	+	0	+	0
=	-107.44

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-485.50 Mil.

Intellia Therapeutics (NAS:NTLA) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Intellia Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

Earnings per Share (Diluted) (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-107.436	-	0)	/	95.502
	=	-1.12

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Intellia Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (Intellia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Executives

Laura Sepp-lorenzino	officer: EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta	officer: EVP, General Counsel	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks	officer: EVP, Chief Business Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark	officer: EVP, Chief Technical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl	officer: EVP, Chief Medical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard	officer: See Remarks	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard	director, officer: President and CEO	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera	officer: EVP, General Counsel	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier	officer: EVP, Chief Operating Officer	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139